Effects of Long-Term Temozolomide Treatment on Glioblastoma and Astrocytoma WHO Grade 4 Stem-Like Cells

Effects of Long-Term Temozolomide Treatment on Glioblastoma and Astrocytoma WHO Grade 4 Stem-Like Cells

Glioblastoma leads to a fatal course within two years in more than two thirds of patients. An essential cornerstone of therapy is chemotherapy with temozolomide (TMZ). The effect of TMZ is counteracted by the cellular repair enzyme O6-methylguanine-DNA methyltransferase (MGMT). The MGMT promoter met...

Full description

Bibliographic Details
Main Authors: Brandner, S. (Author), Ernestus, R.-I (Author), Feldheim, J. (Author), Feldheim, J.J (Author), Glas, M. (Author), Hagemann, C. (Author), Kessler, A.F (Author), Kleinschnitz, C. (Author), Lazaridis, L. (Author), Löhr, M. (Author), Monoranu, C.M (Author), Schulz, E. (Author), Wend, D. (Author)
Format: Article
Language:English
Published: MDPI 2022
Subjects:
astrocytoma
cancer stem cells
glioblastoma
IDH
MGMT
temozolomide
therapy
Online Access:View Fulltext in Publisher

Similar Items

Similar Items